跳转到内容

CEBPD

本页使用了标题或全文手工转换
本页使用了标题或全文手工转换
维基百科,自由的百科全书
CEBPD
識別號
别名CEBPD;, C/EBP-delta, CELF, CRP3, NF-IL6-beta, CCAAT/enhancer binding protein delta, CCAAT enhancer binding protein delta
外部IDOMIM116898 MGI103573 HomoloGene3808 GeneCardsCEBPD
基因位置(人类
8號染色體
染色体8號染色體[1]
8號染色體
CEBPD的基因位置
CEBPD的基因位置
基因座8q11.21起始47,736,913 bp[1]
终止47,738,164 bp[1]
直系同源
物種人類小鼠
Entrez
Ensembl
UniProt
mRNA​序列

NM_005195

NM_007679

蛋白序列

NP_005186

NP_031705

基因位置​(UCSC)Chr 8: 47.74 – 47.74 MbChr 16: 15.71 – 15.71 Mb
PubMed​查找[3][4]
維基數據
檢視/編輯人類檢視/編輯小鼠

CCAAT/增强子结合蛋白δ,简称C/EBP-δCEBPD,是一种在人类中由CEBPD基因编码的蛋白质[5][6]

功能

[编辑]

由这种无内含子基因编码的蛋白质是一种bZIP转录因子,它可以作为同源二聚体与某些DNA调节区结合。它还可以与相关蛋白C/EBP-α形成异二聚体。编码的蛋白质在调节参与免疫炎症反应的基因中很重要,并且可能参与调节与巨噬细胞活化和/或分化相关的基因。[7]

CEBPD参与细胞凋亡细胞增殖的调节。它可能充当肿瘤抑制因子[8]

一项针对小鼠的研究表明,CEBPD在慢性阻塞性肾病进展过程中可防止肾小管损伤和肾小管间质纤维化的发展。[9]

CEBPD基因的功能可以通过基于独立验证的siRNA敲低来有效检查。[10]

相互作用

[编辑]

CEBPD已被证明能与SMAD3相互作用。[11]

参见

[编辑]

参考文献

[编辑]
  1. ^ 1.0 1.1 1.2 GRCh38: Ensembl release 89: ENSG00000221869 - Ensembl, May 2017
  2. ^ 2.0 2.1 2.2 GRCm38: Ensembl release 89: ENSMUSG00000071637 - Ensembl, May 2017
  3. ^ Human PubMed Reference:. National Center for Biotechnology Information, U.S. National Library of Medicine. 
  4. ^ Mouse PubMed Reference:. National Center for Biotechnology Information, U.S. National Library of Medicine. 
  5. ^ Cao Z, Umek RM, McKnight SL. Regulated expression of three C/EBP isoforms during adipose conversion of 3T3-L1 cells. Genes & Development. Sep 1991, 5 (9): 1538–52. PMID 1840554. doi:10.1101/gad.5.9.1538可免费查阅. 
  6. ^ Williams SC, Cantwell CA, Johnson PF. A family of C/EBP-related proteins capable of forming covalently linked leucine zipper dimers in vitro. Genes & Development. Sep 1991, 5 (9): 1553–67. PMID 1884998. doi:10.1101/gad.5.9.1553可免费查阅. 
  7. ^ Entrez Gene: CEBPD CCAAT/enhancer binding protein (C/EBP), delta. 
  8. ^ Gery S, Tanosaki S, Hofmann WK, Koppel A, Koeffler HP. C/EBPdelta expression in a BCR-ABL-positive cell line induces growth arrest and myeloid differentiation. Oncogene. Feb 2005, 24 (9): 1589–97. PMID 15674331. doi:10.1038/sj.onc.1208393可免费查阅. 
  9. ^ Duitman J, Borensztajn KS, Pulskens WP, Leemans JC, Florquin S, Spek CA. CCAAT-enhancer binding protein delta (C/EBPδ) attenuates tubular injury and tubulointerstitial fibrogenesis during chronic obstructive nephropathy. Laboratory Investigation; A Journal of Technical Methods and Pathology. Jan 2014, 94 (1): 89–97. PMID 24247561. doi:10.1038/labinvest.2013.127可免费查阅. 
  10. ^ Munkácsy, Gyöngyi; Sztupinszki, Zsófia; Herman, Péter; Bán, Bence; Pénzváltó, Zsófia; Szarvas, Nóra; Győrffy, Balázs. Validation of RNAi Silencing Efficiency Using Gene Array Data shows 18.5% Failure Rate across 429 Independent Experiments. Molecular Therapy: Nucleic Acids. 2016, 5 (9): e366. ISSN 2162-2531. PMC 5056990可免费查阅. PMID 27673562. doi:10.1038/mtna.2016.66 (英语). 
  11. ^ Choy L, Derynck R. Transforming growth factor-beta inhibits adipocyte differentiation by Smad3 interacting with CCAAT/enhancer-binding protein (C/EBP) and repressing C/EBP transactivation function. The Journal of Biological Chemistry. Mar 2003, 278 (11): 9609–19. PMID 12524424. doi:10.1074/jbc.M212259200可免费查阅. 

阅读

[编辑]

外部链接

[编辑]